垂体后叶素治疗肺结核咯血患者的效果

Pituitrin for pulmonary tuberculosis patients with hemoptysis

目的探讨垂体后叶素治疗肺结核咯血患者的临床效果与安全性。方法收集2015年2月至2016年2月人院的80例肺结核咯血患者，随机分为对照组与实验组。对照组酚妥拉明治疗，实验组则在对照组基础上加用垂体后叶素治疗，比较两组总体治疗效果与复发率、治疗前后肝、肾功能与治疗期间不良反应。结果实验组治疗总有效率显著高于对照组，差异有统计学意义（P〈0．01）；两组复发率差异无统计学意义（P〉0．05）；治疗后，ALT、AST、BUN、Cr与UA水平组间比较均无统计学意义（均P〉0．05）；两组治疗期间不良反应发生率差异无统计学意义（P〉0．05）。结论垂体后叶素治疗肺结核咯血患者临床效果显著，安全性较高，具有借鉴意义。

Objective To investigate the clinical efficacy and safety of pituitrin for pulmonary tuberculosis patients with hemoptysis. Methods Eighty pulmonary tuberculosis patients with hemoptysis admitted into our hospital from February, 2015 to February, 2016 were randomly divided into a control group and an experimental group. The control group were treated with phentolamine; in addition, the experimental group were treated with pituitrin. The treatment effect, relapse rate, the adverse reactions during the treatment, and the liver and kidney functions before and after the treatment were compared between these two groups. Results The total effective rate was significantly higher in the treatment group than in the control group （P 〈 0.01）. There were no statistical differences in the relapse rate and the levels of ALT, AST, BUN, and Cr, the incidence of adverse reactions between the two groups （all P 〉 0.05）. Conclusions Pituitrin for pulmonary tuberculosis patients with hemoptysis is significantly effectively and quite safe, so it is of reference.